AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors

Inclusion Criteria: * Locally unresectable or metastatic carcinoid or pancreatic neuroendocrine tumors. To be classified as having a pancreatic neuroendocrine tumor, patients must have clinical evidence of currently having or having had a primary pancreatic neuroendocrine lesion. * Measurable disease by RECIST criteria * Evidence of progressive disease (by RECIST) within 12 months of study entry. * Tumors must be considered well- or moderately-differentiated. Patients with poorly differentiated neuroendocrine carcinoma of small cell carcinoma are excluded from this study. * Adequate hepatic, renal, bone marrow and glycemic function as outlined in the protocol * Prior treatment with chemotherapy, hepatic artery embolization, surgery or other therapeutic agents is allowed. * Prior or concurrent therapy with somatostatin analogs is permitted: however patients must continue on a stable dose of somatostatin analogs while receiving study treatment. * 18 years of age or older * ECOG performance status 0, 1, or 2 \[Eastern Cooperative Oncology Group \] * Life expectancy of at least 12 weeks * Negative pregnancy test * Ability to sign informed consent Exclusion Criteria: * Poorly differentiated or small cell neuroendocrine carcinomas * Insulin secreting pancreatic neuroendocrine tumors (insulinomas) * Clinically apparent central nervous system metastases or carcinomatous meningitis. * Myocardial infraction in the past 6 months * Major surgery 4 weeks prior to enrollment * Uncontrolled serious medical or psychiatric illness * Pregnant or lactating women. Both men and women of childbearing potential must be advised of the importance of using effective birth control measures during the course of the study. * Prior antitumor therapy within 4 weeks of enrollment (with the exception of somatostatin analogs). * Recent infection requiring systemic anti-infective treatment that was completed 14 days or less prior to enrollment (with the exception of uncomplicated urinary tract infection or upper respiratory tract infection). * Known positive test for human immunodeficiency virus, hepatitis C, chronic or active hepatitis B * Prior IGF or IGF receptor inhibitor therapy \[insulin like growth factor \]